📰 Enveric Bioscience News
Enveric Bioscience News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Enveric Bioscience. Real-time updates on events, politics, business and more.
February 2, 2024
HC Wainwright reissued their buy rating on shares of Enveric Biosciences (NASDAQ:ENVB – Free Report) in a research note issued to investors on Tuesday, Marketbeat reports. The firm currently has a $10.00 target price on the stock. HC Wainwright also issued estimates for Enveric Biosciences’ Q4 2023 earnings at ($1.50) EPS, FY2023 earnings at ($8.10) […]
August 28, 2023
The USPTO issued a patent covering Enveric Biosciences’ (NASDAQ: ENVB) lead candidate EB-373, a psilocin prodrug under development for the treatment of anxiety disorder.
June 2, 2023
Enveric Bioscience CEO Dr. Joseph Tucker joined Steve Darling from Proactive to share news about the company that is looking to help with the opioid crisis...
March 23, 2023
23.03.2023 - Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that ... Seite 1
August 23, 2022
Psychedelic drugs and therapy are fueling the conversations on potentially revolutionary treatment and a paradigm shift for mental health disorders.
July 28, 2022
/PRNewswire/ -- As per Zion Market Research study, The global CBD Consumer Health market was worth USD 10294.1 million in 2021 and is estimated to grow to USD...
March 7, 2022
Enveric BioScience CEO Dr Joseph Tucker joined Steve Darling from Proactive to share news the company has filed its 10th Patent application directed to...
June 9, 2021
There has been a sizable increase in psychedelic companies flocking to stock markets to raise capital in the interest of developing their products and...